Treatment indication and response to standard of care with peginterferon and ribavirin in acute and chronic HCV infection.

Abstract excerpt

Great strides have been made in the treatment of hepatitis C virus (HCV) infection in the past decade. Although there is much focus on the development of new direct-acting antivirals (DAA), interferon and ribavirin remain the backbone of therapy for both acute and chronic HCV infections. While DAA therapy will likely eventually largely replace interferon, in much of the world and for genotype non-1 patients,...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Acute Disease
• Share to Contraindications
• Share to Drug Therapy, Combination